Biomarkers of bone remodelling;Marqueurs biochimiques du remodelage osseux

Bulletin du Cancer

Volumn 100, Issue 11, 2013, Pages 1093-1100

  Debiais, Françoise ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Biomarkers; Bisphosphonates; Bone metastases; Bone turnover; Denosumab

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTIRESORPTIVE AGENT; UNCLASSIFIED DRUG;

BIOLOGICAL MONITORING; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; HOMEOSTASIS; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SOLID TUMOR; TREATMENT RESPONSE;

EID: 84889002853     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1838     Document Type: Article

References (31)

1. Cohen-Solal M, de Vernejoul MC. Marqueurs biochimiques du remodelage osseux. Rev Rhum 2006 ; 73 : 804-6.
2. Garnero P. New biochemical markers of bone turnover in osteoporosis. Med Nucl 2009 ; 33 : 17-27.
3. Richette P, Naveau B, Orcel P. Marqueurs biochimiques du cartilage et de l'os. In : L'actualité rhumatologique. Paris : Elsevier, 2004 (p 275-90).
4. Eastell R, Hannon RA, Cusick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: a 2-year results of the anastrozole, tamoxifen, alone or in combinaition (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-23.
5. Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 32-8.
6. Coleman R, Costa L, Saad F, et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011;80:411-32.
7. Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol 2012; 30:369-78.
8. Koizumi M, Yonese J, Fukui I, et al. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87: 348-51.
9. Jung K, Lein M, Ringsdorf M, et al. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 2006; 176 :1326-31.
10. Ulrich U, Rhiem K, Schmolling J, et al. Cross-linked type 1 collagen C- and N- telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 2001; 264 : 186-90.
11. Wada N, Fujisaki M, Ishii S, et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 2001; 8 : 131-7.
12. Seibel MJ, Koeller M, Van der Velden B, et al. Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 2002; 48:583-8.
13. Pectasides D, Farmakis D, Nicolaou M, et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 2005; 7 : 171-6.
14. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Ntl Cancer Inst 2005;97 : 59-69.
15. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metas-tases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23 : 4925-35.
16. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201.
17. Lipton A, Cook RJ, Major P, et al. Zoledronic acide and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12 :1035-43.
18. Coleman R, Cook R, Saad F, et al. Meta-analysis of effects of zoledronic acid on survival in patients with metastatic bone disease (MBD) and high bone turnover. Cancer Treat Rev 2008; 34 (suppl) :S86.
19. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007;70 :315-9.
20. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3 : 228-36.
21. Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTX levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004;15 : 455-9.
22. Lipton A, Cook R, Brown J, et al. Skeletal-related events and clinical outcomes in patents with bone metastases and normal levels of osteolysis: exploratory analyses. Clin Oncology 2013; 25: 217-26.
23. Lipton A, Chapman JAW, Demers L, et al. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer : results of NCIC CTG MA.14. J Clin Oncol 2011;29:3605-10.
24. Korde LA, Gralow Jr. Can we predict who's at risk for developing bone metastases in breast cancer? J Clin Oncol 2011; 29:3600-4.
25. Dean-Colomb W, Hess KR, Young E, et al. Elevated serum PINP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 2013;137: 631-6.
26. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer; a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
27. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-71.
28. Body JJ, Lipton A, Gralow J, et al. Effects of denoumab in patients with bone metastases with and without previous exposure to bisphos-phonates. J Bone Miner Res 2010;25 :440-6.
29. Coleman RE, Wright J, Houston S, et al. Randomized trial of marker-directed versus standard schedule of zoledronic acid for bone metastases from breast cancer. Proc Am Soc Clin Oncol 2012 ; 30 (suppl) :abstr 511.
30. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 2008;19 :420-32.
31. Van Poznack CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29 : 1221-32.